NewsRelease

HemoglobinRemoval Products Show A Diverse Range of Uses - From Proteomics toViral Antibodies

MONMOUTHJUNCTION, NJ, May 28, 2020 --BiotechSupport Group reports on two journal articles describingthe efficiency and simplicity of their hemoglobindepletion productsfor proteomicanalysis of serum, and the seroprevalenceof virus antibodies.

Thefirst citation is:

Southwell,Rebecca Marie, Kenneth Sherlock, and Matthew Baylis. "Cross-sectionalstudy of British wild deer for evidence of Schmallenberg virusinfection."Veterinary Record (2020).

Schmallenbergvirus (SBV) is an orthobunyavirus that has been detected at highseroprevalence in deer in a number of European countries. The purposeof this study was to survey wild deer across Great Britain for recentevidence of SBV. Postmortem blood samples were tested for SBVantibodies. Because of the presence of Hemoglobin interference inmany samples, the article states “In order to avoid poor qualitysamples yielding false ELISA results, 59 samples estimated to haveabove 50mg/dL and less than 250mg/dL haemoglobin concentration,according to their colour, were selected for treatment withHemogloBind™ (Biotech Support Group, New Jersey, USA).”. The studyreports that the seroprevalence of SBV in the British wild deerpopulation was 13.8 per cent.

Thesecond citation is:

Pawliński,ŝukasz, et al."Proteomicbiomarkers in Gaucher disease."Journalof Clinical Pathology (2020).

Theresearch work was conducted to find new biomarkers and potential drugtargets in Gaucher disease type 1 (GDt1) by analysing serum proteins.For proteomic analysis, the article states “First, the samples werepurified using HemoVoid™ resin (Biotech Support Group, MonmouthJunction, NJ) to remove haemoglobincontamination. The study found 31 proteinsthat significantly differed in concentration between GDt1 patientsand a control group. These were mostly proteins involved in theregulation of inflammatory processes and haemostasis.

“Thesetwo references demonstrate our uniqueness in the proteomic sampleprep business. With two strategies, one that can bind and one thatvoid (not bind), we can very efficiently remove hemoglobin fromblood. Thus we can provide a simple method to remove Hemoglobininterference, as this can often be a problem with many routineclinical analyses. This is becoming especially important with thegrowing use of dried blood cards and point-of-care devices”, statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.

Formore information on all of our Hemoglobin removal products,visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, go tohttp://www.biotechsupportgroup.com

ForBusiness Development, Contact:
MatthewKuruc 732-274-2866,[email protected]